Search

Your search keyword '"Romaní S"' showing total 7 results
Start Over Author "Romaní S" Topic other subheadings::other subheadings::/drug therapy [other subheadings]
7 results on '"Romaní S"'

1. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

Author

Rugo, Hope S, Im, Seock-Ah, Cardoso, Fatima, Cortes, Javier, Curigliano, Giuseppe, Musolino, Antonino, Pegram, Mark D, Bachelot, Thomas, Wright, Gail S, Saura, Cristina, Escrivá-de-Romaní, Santiago, De Laurentiis, Michelino, Schwartz, Gary N, Pluard, Timothy J, Ricci, Francesco, Gwin, William R, Levy, Christelle, Brown-Glaberman, Ursa, Ferrero, Jean-Marc, de Boer, Maaike, Kim, Sung-Bae, Petráková, Katarína, Yardley, Denise A, Freedman, Orit, Jakobsen, Erik H, Gal-Yam, Einav Nili, Yerushalmi, Rinat, Fasching, Peter A, Kaufman, Peter A, Ashley, Emily J, Perez-Olle, Raul, Hong, Shengyan, Rosales, Minori Koshiji, Gradishar, William J, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Institut Català de la Salut, [Rugo HS] University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. [Im SA] Cancer Research Institute, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea. [Cardoso F] Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal. [Cortes J] Quironsalud Group, International Breast Cancer Center (IBCC), Madrid and Barcelona, Spain. Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain. [Curigliano G] Istituto Europeo di Oncologia, IRCCS, University of Milano, Milan, Italy. [Musolino A] Department of Medicine and Surgery, University of Parma, Parma, Italy. Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy. Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy. [Saura C, Escrivá-de-Romaní S] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Cancer Research, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], Oncology, Anticossos monoclonals - Ús terapèutic, Otros calificadores::/uso terapéutico [Otros calificadores], Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Mama - Càncer - Tractament, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados [COMPUESTOS QUÍMICOS Y DROGAS], Other subheadings::/therapeutic use [Other subheadings], Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized [CHEMICALS AND DRUGS], Other subheadings::Other subheadings::/drug therapy [Other subheadings]
Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Final overall survival (OS) in SOPHIA (ClinicalTrials.gov identifier: NCT02492711 ), a study of margetuximab versus trastuzumab, both with chemotherapy, in patients with previously treated human epidermal growth factor receptor 2–positive advanced breast cancer, is reported with updated safety. Overall, 536 patients in the intention-to-treat population were randomly assigned to margetuximab (15 mg/kg intravenously once every 3 weeks; n = 266) plus chemotherapy or trastuzumab (6 mg/kg intravenously once every 3 weeks after a loading dose of 8 mg/kg; n = 270) plus chemotherapy. Primary end points were progression-free survival, previously reported, and OS. Final OS analysis was triggered by 385 prespecified events. The median OS was 21.6 months (95% CI, 18.89 to 25.07) with margetuximab versus 21.9 months (95% CI, 18.69 to 24.18) with trastuzumab (hazard ratio [HR], 0.95; 95% CI, 0.77 to 1.17; P = .620). Preplanned, exploratory analysis of CD16A genotyping suggested a possible improvement in OS for margetuximab in CD16A-158FF patients versus trastuzumab (median OS, 23.6 v 19.2 months; HR, 0.72; 95% CI, 0.52 to 1.00) and a possible improvement in OS for trastuzumab in CD16A-158VV patients versus margetuximab (median OS, 31.1 v 22.0 months; HR, 1.77; 95% CI, 1.01 to 3.12). Margetuximab safety was comparable with trastuzumab. Final overall OS analysis did not demonstrate margetuximab advantage over trastuzumab. Margetuximab studies in patients with human epidermal growth factor receptor 2–positive breast cancer with different CD16A allelic variants are warranted.

Published
2023

2. Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

Author

Duro-Sánchez, Santiago, Nadal-Serrano, Mercedes, Lalinde-Gutiérrez, Marta., Arenas, Enrique J, Bernadó Morales, Cristina, Morancho, Beatriz, Escorihuela, Marta, Pérez-Ramos, Sandra, Escrivá-de-Romaní, Santiago, Gandullo-Sánchez, Lucía, Pandiella, Atanasio, Esteve-Codina, Anna, Rodilla, Verónica, Dijcks, Fred .A., Dokter, Wim .H.A., Cortés, Javier, Saura, Cristina, Arribas, Joaquín V, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Duro-Sánchez S, Lalinde-Gutiérrez M] Preclinical and Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain. [Nadal-Serrano M, Arenas EJ, Bernadó Morales C, Morancho B] Preclinical and Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain. [Escorihuela M, Pérez-Ramos S, Rodilla V, Cortés J] Preclinical and Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Escrivá-de-Romaní S] Breast Cancer and Melanoma Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Gandullo-Sánchez L] Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain. Breast Cancer and Melanoma Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Saura C] Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain. [Arribas J] Preclinical and Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain. Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain. Universitat Pompeu Fabra (UPF), Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, American Breast Cancer Foundation, Instituto de Salud Carlos III, Fundación Mutua Madrileña, and Asociación Española Contra el Cáncer

Subjects
Cancer Research, Immunoconjugates, Receptor, ErbB-2, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Mama--Càncer--Aspectes genètics, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Antineoplastic Agents, Breast Neoplasms, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Cathepsin B, Medicaments antineoplàstics, Mama--Tumors, Cell Line, Tumor, Humans, Animals, Other subheadings::/therapeutic use [Other subheadings], Mama--Càncer--Tractament, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], Anticossos monoclonals - Ús terapèutic, Otros calificadores::/uso terapéutico [Otros calificadores], Chemical Actions and Uses::Toxic Actions::Noxae::Immunoconjugates [CHEMICALS AND DRUGS], acciones y usos químicos::acciones tóxicas::noxas::inmunoconjugados [COMPUESTOS QUÍMICOS Y DROGAS], Trastuzumab, Xenograft Model Antitumor Assays, Oncology, Mama - Càncer - Tractament, Female
Abstract

Antibody–drug conjugates (ADC) are antineoplastic agents recently introduced into the antitumor arsenal. T-DM1, a trastuzumab-based ADC that relies on lysosomal processing to release the payload, is approved for HER2-positive breast cancer. Next-generation ADCs targeting HER2, such as [vic-]trastuzumab duocarmazine (SYD985), bear linkers cleavable by lysosomal proteases and membrane-permeable drugs, mediating a bystander effect by which neighboring antigen-negative cells are eliminated. Many antitumor therapies, like DNA-damaging agents or CDK4/6 inhibitors, can induce senescence, a cellular state characterized by stable cell-cycle arrest. Another hallmark of cellular senescence is the enlargement of the lysosomal compartment. Given the relevance of the lysosome to the mechanism of action of ADCs, we hypothesized that therapies that induce senescence would potentiate the efficacy of HER2-targeting ADCs. Treatment with the DNA-damaging agent doxorubicin and CDK4/6 inhibitor induced lysosomal enlargement and senescence in several breast cancer cell lines. While senescence-inducing drugs did not increase the cytotoxic effect of ADCs on target cells, the bystander effect was enhanced when HER2-negative cells were cocultured with HER2-low cells. Knockdown experiments demonstrated the importance of cathepsin B in the enhanced bystander effect, suggesting that cathepsin B mediates linker cleavage. In breast cancer patient-derived xenografts, a combination treatment of CDK4/6 inhibitor and SYD985 showed improved antitumor effects over either treatment alone. These data support the strategy of combining next-generation ADCs targeting HER2 with senescence-inducing therapies for tumors with heterogenous and low HER2 expression., This work was supported by Breast Cancer Research Foundation (BCRF-20-008), Instituto de Salud Carlos III (project reference numbers AC15/00062, CB16/12/00449 and PI19/01181), the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Fundacion Mutua Madrilena and Asociación ~ Española Contra el Cáncer. S. Duro-Sanchez is supported by the Spanish Ministerio de Universidades by the grant Formacion de Profesorado Universitario (FPU20/05388). A. Esteve-Codina is funded by ISCIII /MINECO (PT17/0009/0019) and co-funded by FEDER.

Published
2022

3. Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response

Author

Nikaoly Ciriaco, Esther Zamora, Santiago Escrivá-de-Romaní, Ignacio Miranda Gómez, José Jiménez Flores, Cristina Saura, Hillary Sloane, Anna Starus, Johannes Fredebohm, Lucy Georgieva, Graham Speight, Frederick Jones, Santiago Ramón y Cajal, Martín Espinosa-Bravo, Vicente Peg, Institut Català de la Salut, [Ciriaco N] Pathology Department, Hospital del Mar, Barcelona, Spain. Universidad Autónoma de Barcelona, Barcelona, Spain. [Zamora E] Universitat Autònoma de Barcelona, Bellaterra, Spain. Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Escrivá-de-Romaní S] Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Miranda Gómez I] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Jiménez Flores J] Molecular Oncology Lab. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Saura C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ramón Y Cajal S, Peg V] Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain. [Espinosa-Bravo M] Unitat de Patologia Mamària, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Circulating tumor DNA, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], Liquid biopsy, Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::Cell-Free Nucleic Acids::Circulating Tumor DNA [CHEMICALS AND DRUGS], Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Marcadors tumorals, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], factores biológicos::biomarcadores::marcadores tumorales [COMPUESTOS QUÍMICOS Y DROGAS], Other subheadings::Other subheadings::/drug therapy [Other subheadings], nucleótidos y nucleósidos de ácidos nucleicos::ácidos nucleicos::ácidos nucleicos libres de células::ADN tumoral circulante [COMPUESTOS QUÍMICOS Y DROGAS], Therapeutics::Combined Modality Therapy::Neoadjuvant Therapy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Breast cancer, Oncology, Neoadjuvant therapy, Pathologic complete response, Mama - Càncer - Tractament, Mama - Càncer - Aspectes genètics, terapéutica::tratamiento combinado::tratamiento neoadyuvante [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Biological Factors::Biomarkers::Biomarkers, Tumor [CHEMICALS AND DRUGS]
Abstract

Breast cancer; Liquid biopsy; Neoadjuvant therapy Càncer de mama; Biòpsia líquida; Teràpia neoadjuvant Cáncer de mama; Biopsia líquida; Terapia neoadyuvante Background: Although the standard of care is to perform surgery of primary breast cancer (BC) after neoadjuvant chemotherapy (NAC), for certain patients achieving clinical complete response (cCR) and pathologic complete response (pCR), omission of surgical treatment may be an option. Levels of circulating tumor DNA (ctDNA) during and after therapy could identify patients achieving minimal residual disease. In this study, we evaluated whether ctDNA clearance during NAC could be a correlate to effective response in human epidermal growth factor receptor 2 positive (HER2+) and triple-negative (TN) BC patients. Methods: A prospective study was conducted to identify patient-specific PIK3CA and TP53 mutations in tissue using next-generation sequencing, which could then be used to track the presence/absence of mutations prior to, during, and following NAC using Sysmex SafeSEQ technology. All patients underwent a surgical excision after NAC, and pCR was assessed. Results: A total of 29 TN and HER2+ BC patients were examined and 20 that carried mutations in the PIK3CA and/or TP53 genes were recruited. Overall, 19 of these 20 patients harbored at least one tumor-specific mutation in their plasma at baseline. After NAC, 15 patients (75.0%) achieved pCR according to the histopathologic evaluation of the surgical specimen, and 15 patients (75.0%) had a cCR; 18 of 20 patients (90.0%) had concordant pCR and cCR. The status of ‘no mutation detected’ (NMD) following NAC in cCR patients correctly identified the pCR in 14 of 15 patients (93.33%), as well as correctly ruled out pCR in three patients, with an accuracy of 89.47%. During the 12-month follow-up after surgery, 40 plasma samples collected from 15 patients all showed no detectable ctDNA (NMD), and no patient recurred. Conclusion: These findings prompt further research of the value of ctDNA for non-invasive prediction of clinical/pathological response, raising the possibility of sparing surgery following NAC in selected BC patients. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a grant from Sysmex Inostics, Inc. The sponsor coordinated data collection from study centers, and funded the statistical analysis and medical writing assistance.

Published
2022

4. Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends

Author

Kreina Sharela Vega Cano, David Humberto Marmolejo Castañeda, Santiago Escrivá-de-Romaní, Cristina Saura, Institut Català de la Salut, [Vega Cano KS, Marmolejo Castañeda DH] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Escrivá-de-Romaní S, Saura C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], Cancer Research, Anticossos monoclonals - Ús terapèutic, Oncology, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Mama - Càncer - Tractament, Medicaments antineoplàstics - Ús terapèutic, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS], aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados [COMPUESTOS QUÍMICOS Y DROGAS], Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS], Other subheadings::Other subheadings::/drug therapy [Other subheadings], Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized [CHEMICALS AND DRUGS]
Abstract

Càncer de mama metastàtic; Teràpies dirigides; Trastuzumab Metastatic breast cancer; Targeted therapies; Trastuzumab Cáncer de mama metastásico; Terapias dirigidas; Trastuzumab Approximately 20% of breast cancers (BC) overexpress human epidermal growth factor receptor 2 (HER2). This subtype of BC is a clinically and biologically heterogeneous disease that was associated with an increased risk for the development of systemic and brain metastases and poor overall survival before anti-HER2 therapies were developed. The standard of care was dual blockade with trastuzumab and pertuzumab as first-line followed by TDM-1 as second-line. However, with the advent of new HER2-targeted monoclonal antibodies, tyrosine kinase inhibitors and antibody- drug conjugates, the clinical outcomes of patients with HER2-positive BC have changed dramatically in recent years, leading to a paradigm shift in the treatment of the disease. Notably, the development of new-generation ADCs has led to unprecedented results compared with T-DM1, currently establishing trastuzumab deruxtecan as a new standard of care in second-line. Despite the widespread availability of HER2-targeted therapies, patients with HER2-positive BC continue to face the challenges of disease progression, treatment resistance, and brain metastases. Response rate and overall life expectancy decrease with each additional line of treatment, and tumor heterogeneity remains an issue. In this review, we update the new-targeted therapeutic options for HER2-positive BC and highlight the future perspectives of treatment in this setting.

Published
2022
Full Text
View/download PDF

5. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Author

Institut Català de la Salut, [Bellet M, Escrivá-de-Romaní S] Hospital Universitari Vall d'Hebron, Barcelona, Spain. Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. [Ahmad F, Alcalde M, Ruíz I] Vall d’Hebron Institut de Recerca, Barcelona, Spain. Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Villanueva R] Institut Català d'Oncologia, Barcelona, Spain. Hospital Moisès Broggi, Barcelona, Spain. [Valdivia C] Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Palomino-Doza J] Hereditary Cardiopathies Unit, Hospital Universitario 12 de Octubre, Madrid, Spain. [Ruiz A] Institut de Neuropsiquiatria i Addiccions, Hospital del Mar, Barcelona, Spain. Institut Hospital de Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain. [Azaro A] Servei d’Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. [Aguilar J] Servei d’Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Martín A] Unitat de Cures Pal•liatives, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Reyes V] Servei d’ Oncologia Radioteràpica, Hospital Universitari Vall d'Hebron, Barcelona, Spain., and Hospital Universitari Vall d'Hebron

Subjects
Otros calificadores::/uso terapéutico [Otros calificadores], Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Interactions [PHENOMENA AND PROCESSES], Aminoácidos, Péptidos y Proteínas::Péptidos::Péptidos y Proteínas de Señalización Intracelular::Proteínas Inhibidoras de las Quinasas Dependientes de la Ciclina [COMPUESTOS QUÍMICOS Y DROGAS], Mama - Càncer - Quimioteràpia, Other subheadings::/therapeutic use [Other subheadings], Neoplasias::Neoplasias por Localización::Neoplasias de la Mama [ENFERMEDADES], Quinases dependents de ciclina - Inhibidors, Amino Acids, Peptides, and Proteins::Peptides::Intracellular Signaling Peptides and Proteins::Cyclin-Dependent Kinase Inhibitor Proteins [CHEMICALS AND DRUGS], Other subheadings::Other subheadings::/drug therapy [Other subheadings], Fenómenos Fisiológicos::Fenómenos Farmacológicos y Toxicológicos::Fenómenos Farmacológicos::Interacciones de Drogas [FENÓMENOS Y PROCESOS], Medicaments - Interacció, Otros calificadores::Otros calificadores::/tratamiento farmacológico [Otros calificadores]
Published
2021

6. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Author

Institut Català de la Salut, [Bellet M, Escrivá-de-Romaní S] Hospital Universitari Vall d'Hebron, Barcelona, Spain. Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. [Ahmad F, Alcalde M, Ruíz I] Vall d’Hebron Institut de Recerca, Barcelona, Spain. Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Villanueva R] Institut Català d'Oncologia, Barcelona, Spain. Hospital Moisès Broggi, Barcelona, Spain. [Valdivia C] Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Palomino-Doza J] Hereditary Cardiopathies Unit, Hospital Universitario 12 de Octubre, Madrid, Spain. [Ruiz A] Institut de Neuropsiquiatria i Addiccions, Hospital del Mar, Barcelona, Spain. Institut Hospital de Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain. [Azaro A] Servei d’Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. [Aguilar J] Servei d’Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Martín A] Unitat de Cures Pal•liatives, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Reyes V] Servei d’ Oncologia Radioteràpica, Hospital Universitari Vall d'Hebron, Barcelona, Spain., and Hospital Universitari Vall d'Hebron

Subjects
Otros calificadores::/uso terapéutico [Otros calificadores], Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Interactions [PHENOMENA AND PROCESSES], Aminoácidos, Péptidos y Proteínas::Péptidos::Péptidos y Proteínas de Señalización Intracelular::Proteínas Inhibidoras de las Quinasas Dependientes de la Ciclina [COMPUESTOS QUÍMICOS Y DROGAS], Mama - Càncer - Quimioteràpia, Other subheadings::/therapeutic use [Other subheadings], Neoplasias::Neoplasias por Localización::Neoplasias de la Mama [ENFERMEDADES], Quinases dependents de ciclina - Inhibidors, Amino Acids, Peptides, and Proteins::Peptides::Intracellular Signaling Peptides and Proteins::Cyclin-Dependent Kinase Inhibitor Proteins [CHEMICALS AND DRUGS], Other subheadings::Other subheadings::/drug therapy [Other subheadings], Fenómenos Fisiológicos::Fenómenos Farmacológicos y Toxicológicos::Fenómenos Farmacológicos::Interacciones de Drogas [FENÓMENOS Y PROCESOS], Medicaments - Interacció, Otros calificadores::Otros calificadores::/tratamiento farmacológico [Otros calificadores]
Published
2021

7. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Author

Isabel Ruiz, Analia Azaro, Encarna Adrover, Xavier Gonzalez, Faten Ahmad, Ada I. Ruiz, Antonia Perelló, Cristina Hernando, Ainhara Lahuerta, Maria Valls-Margarit, Miguel Ángel Seguí, Carolina Valdivia, Pilar Zamora, Santiago Escrivá-de-Romaní, Rafael Villanueva, Pamela Céliz, Meritxell Bellet, Julián Palomino-Doza, Helena Masanas, V. Reyes, Maria Vidal, Joaquín Gavilá, María Soledad Gómez Alcalde, Josep Lluís Parra, Juan Aguilar, Anastasi Martín, Miguel Gil, Lorena de la Peña, Institut Català de la Salut, [Bellet M, Escrivá-de-Romaní S] Hospital Universitari Vall d'Hebron, Barcelona, Spain. Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. [Ahmad F, Alcalde M, Ruíz I] Vall d’Hebron Institut de Recerca, Barcelona, Spain. Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Villanueva R] Institut Català d'Oncologia, Barcelona, Spain. Hospital Moisès Broggi, Barcelona, Spain. [Valdivia C] Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Palomino-Doza J] Hereditary Cardiopathies Unit, Hospital Universitario 12 de Octubre, Madrid, Spain. [Ruiz A] Institut de Neuropsiquiatria i Addiccions, Hospital del Mar, Barcelona, Spain. Institut Hospital de Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain. [Azaro A] Servei d’Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. [Aguilar J] Servei d’Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Martín A] Unitat de Cures Pal•liatives, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Reyes V] Servei d’ Oncologia Radioteràpica, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, and UAM. Departamento de Medicina

Subjects
0301 basic medicine, Background information, medicine.medical_specialty, aminoácidos, péptidos y proteínas::péptidos::péptidos y proteínas de señalización intracelular::proteínas inhibidoras de cinasas dependientes de ciclinas [COMPUESTOS QUÍMICOS Y DROGAS], Oncologia, palbociclib, Medicina, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], Ribociclib, Palbociclib, Review, Mama - Càncer - Quimioteràpia, Other subheadings::Other subheadings::/drug therapy [Other subheadings], lcsh:RC254-282, QT interval, Càncer de mama, 03 medical and health sciences, fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::interacciones farmacológicas [FENÓMENOS Y PROCESOS], Breast cancer, 0302 clinical medicine, CDK4/6 Inhibitors in Breast Cancer: A Lot of Data, A Lot of Questions, breast cancer, medicine, In patient, Other subheadings::/therapeutic use [Other subheadings], ribociclib, Intensive care medicine, Adverse effect, Otros calificadores::Otros calificadores::/tratamiento farmacológico [Otros calificadores], business.industry, Otros calificadores::/uso terapéutico [Otros calificadores], lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Medicaments - Interacció, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Concomitant, Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Interactions [PHENOMENA AND PROCESSES], Quinases dependents de ciclina - Inhibidors, Amino Acids, Peptides, and Proteins::Peptides::Intracellular Signaling Peptides and Proteins::Cyclin-Dependent Kinase Inhibitor Proteins [CHEMICALS AND DRUGS], business, CDK inhibitors
Abstract

Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed., The project received funding from Novartis, Pfizer, Grunenthal, Esteve and Kyowa Hakko Kirin; none of the funding bodies participated in the workshop discussion. The authors would like to thank i2e3 research institute for providing editorial assistance on behalf of SOLTI.

Catalog

Books, media, physical & digital resources
See catalog results